Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 907 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: MS Contin Clear all
Completed Phase 4 Interventional Results available

Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain

NCT01207596
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Hydromorphone
Drug
Lead sponsor
International Clinical Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Leawood, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2012 · Synced Sep 17, 2026, 5:44 PM EDT
Terminated Early Phase 1 Interventional

Multimodal Pain Management Following Primary TKA

NCT02369523
View directory record Official record
Conditions
Pain
Interventions
Exparel, Ropivacaine cocktail (PIC), Bupivacaine
Drug
Lead sponsor
University of Utah
Other
Eligibility
40 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 17, 2026, 5:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Low Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department

NCT01835262
View directory record Official record
Conditions
Pain
Interventions
Morphine, Ketamine
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 17, 2026, 5:44 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Hydromorphone Pharmacokinetic-Pharmacodynamic Fingerprint

NCT01123486
View directory record Official record
Conditions
Pain, Ventilatory Depression
Interventions
hydromorphone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
21 Years to 30 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Sep 17, 2026, 5:44 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Neonatal Abstinence Syndrome

NCT01723722
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Methadone, Diluted Deodorized Tincture of Opium
Drug
Lead sponsor
Eastern Maine Medical Center
Other
Eligibility
1 Day to 6 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bangor, Maine
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Sep 17, 2026, 5:44 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)

NCT05119569
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Fenebrutinib, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Fullerton, California • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 17, 2026, 5:44 PM EDT
Completed Not applicable Interventional

Study of Intensive, Home-Based Family Therapy to Improve Illness Management in Youth With Diabetes

NCT00372814
View directory record Official record
Conditions
Diabetes Mellitus, Insulin Dependent
Interventions
Intensive Home-Based Family Therapy, Supportive Telephone Calls
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
10 Years to 17 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 17, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Results available

Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

NCT01210352
View directory record Official record
Conditions
Post Operative Pain
Interventions
oxymorphone HCl
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
0 Years to 12 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
8
States / cities
Tucson, Arizona • Little Rock, Arkansas • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Sep 17, 2026, 5:44 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Epidural Methadone in Healthy Volunteers

NCT03525509
View directory record Official record
Conditions
Pain, Acute
Interventions
Methadone hydrochloride, Morphine Sulfate
Drug
Lead sponsor
simon.haroutounian
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 17, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

NCT00354835
View directory record Official record
Conditions
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Botryoid-Type Embryonal Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Localized Childhood Soft Tissue Sarcoma, Rhabdomyosarcoma, Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7, Stage II Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7
Interventions
Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Questionnaire Administration, Radiation Therapy, Vincristine Sulfate
Drug · Biological · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 49 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
196
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 142 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Sep 17, 2026, 5:44 PM EDT
Active, not recruiting Not applicable Interventional

Assessment of a Non-invasive Device in the Management of Open Abdomen (AbCLO)

NCT06242925
View directory record Official record
Conditions
Open Abdomen
Interventions
AbCLO (Abdominal Wall Closure) Device
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Sep 17, 2026, 5:44 PM EDT
Completed Phase 4 Interventional

Multimodal Analgesia Effect on Post Surgical Patient

NCT04240626
View directory record Official record
Conditions
Obesity, Morbid, Surgery, Bariatric Surgery Candidate
Interventions
Neurontin, Dilaudid Injectable Product, Marcaine Injectable Product, Oxycodone Hydrochloride, Hycet 7.5Mg-325Mg/15Ml Solution, Zofran Injection, Scopolamine patch, Ativan, Flexeril Oral Product, Tylenol Suspension
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
35 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 17, 2026, 5:44 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Remibrutinib oral treatment, Ocrelizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
44
States / cities
Scottsdale, Arizona • Irvine, California • Washington D.C., District of Columbia + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 17, 2026, 5:44 PM EDT
Completed Phase 4 Interventional Results available

Reduction of Bladder Injection Pain With Belladonna Opiate Suppository

NCT02600715
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urinary Bladder, Neurogenic, Painful Bladder Syndrome
Interventions
Onabotulinumtoxin A (BoNT), belladonna, Morphine, Placebo, Active B&O suppository of belladonna
Drug
Lead sponsor
Edgar LeClaire, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Sep 17, 2026, 5:44 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients

NCT02321319
View directory record Official record
Conditions
Chronic Pain
Interventions
Hydromorphone HCl ER Tablets
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
7 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Sep 17, 2026, 5:44 PM EDT
Completed No phase listed Observational

Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals

NCT00218309
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Hydromorphone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 17, 2026, 5:44 PM EDT
Completed Phase 1Phase 2 Interventional

Codeine in Sickle Cell Disease

NCT00174538
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Codeine (30 mg)
Drug
Lead sponsor
PriCara, Unit of Ortho-McNeil, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Sep 17, 2026, 5:44 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions
Tolebrutinib, Placebo, Teriflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
52
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 17, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Genetic Effects on Dopamine Response to an Opiate

NCT01878006
View directory record Official record
Conditions
Polymorphism-Genetic, Pain, Addiction
Interventions
Morphine, Placebo
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 55 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 17, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intrathecal Hydromorphone for Labor Analgesia

NCT01598506
View directory record Official record
Conditions
Labor Pain
Interventions
Hydromorphone
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 17, 2026, 5:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Reduction in Pain Intensity Following IV or Oral Pain-relieving Products

NCT02678416
View directory record Official record
Conditions
Pain
Interventions
IV Acetaminophen (Treatment A), Oral Acetaminophen (Treatment B), Placebo (Treatment C), Morphine (Treatment D)
Drug · Other
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 17, 2026, 5:44 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pain Management in Outpatient Urologic Procedures

NCT03393364
View directory record Official record
Conditions
Urologic Diseases
Interventions
Oxycodone, Ketorolac
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 17, 2026, 5:44 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects

NCT00765856
View directory record Official record
Conditions
Chronic Pain
Interventions
Oxymorphone ER
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
13
States / cities
Little Rock, Arkansas • Stanford, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Sep 17, 2026, 5:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Aprepitant Effects on Oxycodone Response

NCT00999544
View directory record Official record
Conditions
Narcotic Abuse
Interventions
Aprepitant 0mg, Aprepitant 40mg, Aprepitant 200mg, Oxycodone 0mg, p.o., Oxycodone 20mg, p.o., Oxycodone 40mg, p.o., Oxycodone 0mg, IN, Oxycodone 15mg, IN, Oxycodone 30mg, IN
Drug
Lead sponsor
Sharon Walsh
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 17, 2026, 5:44 PM EDT